Sana Biotechnology (SANA) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Sana Biotechnology is set to release its Q2 2025 earnings results on August 14th, with analysts expecting a loss of ($0.20) per share.
• The company recently reported ($0.20) EPS for its last quarter, exceeding the consensus estimate of ($0.22).
• Institutional investors own approximately 88.23% of Sana Biotechnology's stock, with AQR Capital Management recently increasing its holdings by 49.8%.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.02. On average, analysts expect Sana Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sana Biotechnology Stock Performance

Shares of Sana Biotechnology stock traded up $0.03 during trading hours on Friday, hitting $3.00. The company's stock had a trading volume of 8,476,364 shares, compared to its average volume of 5,977,702. The company has a market cap of $676.43 million, a PE ratio of -3.41 and a beta of 1.90. The business has a 50 day moving average price of $3.47 and a two-hundred day moving average price of $2.70. Sana Biotechnology has a 12-month low of $1.26 and a 12-month high of $7.30.

Analyst Ratings Changes

Several research firms have weighed in on SANA. JMP Securities restated a "market outperform" rating and issued a $5.00 price target on shares of Sana Biotechnology in a research note on Tuesday, June 24th. Morgan Stanley initiated coverage on shares of Sana Biotechnology in a research report on Thursday, July 3rd. They set an "overweight" rating and a $12.00 target price for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $11.00 target price on shares of Sana Biotechnology in a research note on Thursday, April 24th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Sana Biotechnology presently has a consensus rating of "Buy" and a consensus target price of $9.17.

Hedge Funds Weigh In On Sana Biotechnology

A hedge fund recently raised its stake in Sana Biotechnology stock. AQR Capital Management LLC lifted its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 49.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 573,146 shares of the company's stock after acquiring an additional 190,483 shares during the quarter. AQR Capital Management LLC owned 0.25% of Sana Biotechnology worth $963,000 as of its most recent SEC filing. Institutional investors and hedge funds own 88.23% of the company's stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.